PubMed Health⌕ Search

Biomedical subjects

W L Dewey

Publications and source records attributed to W L Dewey.

At least 73 records · Page 4Linked to original sources

A characterization of the antinociception produced by intracerebroventricular injection of 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate in mice.

There is evidence that 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate (TMB-8) acts as an intracellular Ca++ antagonist producing decreases in free intracellular Ca++ and inhibiting many cellular processes dependent upon intracellular Ca++. Intracerebroventricularly administered TMB-8 was active in the mouse tail-flick test (ED50 = 50 micrograms), and this antinociceptive response was antagonized by naloxone (AD50 = 0.28 mg/kg s.c.), Ca++ (0.2-0.4 mumol i.c.v.) and, to a lesser degree, by ethylene glycol bis (beta-aminoethyl ether)N,N1-tetraacetic acid (0.02 and 0.06 mumol i.c.v.). TMB-8 (i.c.v.) was only marginally active in the p-phenylquinone test. The potency of TMB-8 (i.c.v.) was potentiated 10-fold in morphine-tolerant mice in the tail-flick test (ED50 = 2.5 micrograms). TMB-8 inhibited contraction of stimulated ilea (IC50 = 2.2 microM), an effect which was neither antagonized nor reversed by naloxone (1 microM). TMB-8 did not potentiate morphine, or was it potentiated by morphine, in the stimulated guinea pig ileum. Procaine, but not lidocaine showed dose-dependent activity in the tail-flick and p-phenylquinone tests (ED50 values, 136 and 83 micrograms, respectively, i.c.v.). The antinociception produced by procaine (i.c.v.) in the tail-flick test was antagonized by naloxone (AD50 = 0.4 mg/kg s.c.) Lidocaine (100 micrograms i.c.v.) produced only 30% maximum possible effect in the tail-flick tests, and was inactive in p-phenylquinone tests. Doses of lidocaine greater than 100 micrograms i.c.v. resulted in lethality of greater than 50% of the animals tested. Thus, the activity of TMB-8 resembles that of opiates in that both are antagonized by Ca++ or naloxone in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)

Analgesia↗

Cannabinoid pharmacology.

The pharmacology of the cannabinoids is characterized by at least two very provocative phenomena. First, the multiplicity of effects. As I have mentioned throughout this review, most of these effects are due to actions on the central nervous system. The major problem in the search for a therapeutic agent in this series has been due to the inability to find a cannabinoid with the therapeutic action at doses below those that produce side effects. The high lipid solubility of the cannabinoids allows them to be distributed throughout the brain at reasonable doses. The second aspect of their pharmacology worthy of special mention is their low toxicity. Throughout this review, I have indicated that the minimal effective dose of delta 9-THC for a particular pharmacological effect in animals was higher than that usually consumed by man. Yet, in almost all cases, it was much lower than the dose which produced toxic effects in the same species. These two characteristics of the animal pharmacology of cannabinoids carry over to humans. For instance, each of the cannabinoids tested in man causes many side effects at active doses and lethal effects of overdose by humans are nonexistent or rare. Toxicity following chronic use may be a different issue. A great deal of work has been carried out in an attempt to characterize the pharmacological effects of cannabinoids. It is clear from the material reviewed in this article that most if not all of the predominant effects of cannabinoids in whole animals are due to the direct effects of these compounds on the central nervous system. Our state of knowledge is too limited to rule out the possibility that they also produce effects on certain peripheral organs. It is expected that the majority of these effects will be shown to be due to the interaction of the cannabinoids with the neuronal innervation of the organ rather than directly with the organ tissue itself. Very high doses of cannabinoids just like all active drugs have an effect on many organ systems. These are toxicologic not pharmacologic and are nonspecific. The effects of cannabinoids at the molecular level have been reviewed by Martin (182a) in this series. This type of research is expected to elucidate the mechanism of action of cannabinoids at the cellular level. It is clear that the cannabinoids produce a unique behavioral syndrome in laboratory animals and in man.(ABSTRACT TRUNCATED AT 400 WORDS)

Aggression↗

Morphine dependence and diabetes. I. The development of morphine dependence in streptozotocin-diabetic rats and spontaneously diabetic C57BL/KsJ mice.

Spontaneously diabetic (db/db) and nondiabetic (db/m+, m+/m+) C57BL/KsJ mice were made dependent by a 9-day exposure to increasing doses of morphine-admixed food. Radioimmunoassay for morphine demonstrated that diabetic mice had significantly greater brain accumulations of morphine than nondiabetic littermates after morphine-admixed food. Despite their greater brain levels of morphine, diabetic mice showed significantly fewer behavioral signs of withdrawal after naloxone, and lost significantly less weight at 60 min after naloxone than their nondiabetic littermates. Streptozotocin-diabetic and nondiabetic rats rendered dependent by a 6-day i.p. infusion of morphine had equal brain levels of morphine, but the diabetic rats showed significantly fewer behavioral signs of withdrawal than nondiabetic rats at 24 and 48 hr after the end of the infusion. These results indicate that spontaneously diabetic mice and streptozotocin-diabetic rats were both significantly less physically dependent upon morphine than their respective nondiabetic controls and support our conclusion that the development of physical dependence upon morphine is reduced in experimental models of diabetes.

Animals↗

Morphine dependence and diabetes. II. Alterations of normorphine potency in the guinea-pig ileum and mouse vas deferens and of ileal morphine dependence by changes in glucose concentration.

The effects of glucose in vitro at concentrations of 100, 200 and 400 mg/dl on responses of the guinea-pig ileum and mouse vas deferens to opiates were studied. Responses of the electrically stimulated ileum to normorphine were significantly reduced (IC50 values: 26.3 +/- 4.3, 40.5 +/- 3.7 and 71.8 +/- 16.6 nM) as the glucose concentration increased, whereas the potency of normorphine was not affected by equimolar substitutions of glucose with the nonmetabolizable sugar 3-O-methylglucose. The potency of naloxone to induce withdrawal contractions of ilea incubated in Ringer's solution for 3 or 4.5 hr with 1 microM morphine was also significantly decreased as the concentration of glucose in the incubations increased, indicating a reduction of acute dependence development by high glucose. The potency of normorphine was also reduced by increasing concentrations of glucose in electrically stimulated vasa deferentia from nondiabetic (db/m+, m+/m+) C57BL/KsJ mice (IC50 values: 0.53 +/- 0.01, 0.77 +/- 0.01 and 1.84 +/- 0.03 nM), but not in vasa deferentia from their diabetic (db/db) littermates. These results support our hypothesis that the decreased sensitivity to morphine and decreased development of physical dependence on morphine in in vivo models of diabetes reported previously by our laboratory is due primarily to the hyperglycemia associated with diabetes.

Animals↗

Antinociceptive activity of salmon calcitonin injected intraventricularly in mice: modulation of morphine antinociception.

Salmon calcitonin (sCT) was tested i.v.t. for its ability to produce antinociception in mice as quantitated by the tail-flick, hot-plate and p-phenylquinone (PPQ) writhing tests. sCT from two sources, Bachem (Torrance, CA) and Armour Pharmaceutical Co. (Chicago, IL), was shown to have naloxone reversible antinociceptive activity in the tail-flick and hot-plate tests. However, the sCT analgesic activity in the PPQ test was only partially naloxone reversible. sCT produced a naloxone reversible potentiation of doses of morphine that had low analgesic activity, but sCT failed to potentiate higher doses of morphine in the tail-flick test. sCT has a similar biphasic effect on morphine in the PPQ test in that low doses of morphine were selectively potentiated. However, the potentiation in the PPQ test was not naloxone reversible. sCT was shown not to be cross-tolerant to morphine in the PPQ test. Thus, sCT appears to produce its antinociceptive effects via interaction with both opiate and nonopiate mechanisms.

Analgesics↗

Comparison of the ability of opioid analgesics to increase endogenous opioid-like activity in the cerebrospinal fluid of rabbits.

We have previously demonstrated that the acute administration of morphine increases the level of endogenous substances, which have antinociceptive activity, in cerebrospinal fluid (CSF). The present study was conducted to determine whether other opioid analgesics exert a similar effect. CSF was withdrawn from the cisterna magna of anesthetized rabbits before and after s.c. injections of meperidine, pentazocine, levorphanol and methadone, and was bioassayed for opioid-like activity in the mouse tail-flick and phenylquinone writhing tests. The opioid-like activity of CSF taken 60 min after meperidine (50 mg/kg) was significantly increased in both bioassays, and the CSF level of meperidine was insufficient to account for this effect. Pentazocine (25-75 mg/kg) also significantly increased opioid-like activity in rabbit CSF, but the effects of methadone (5-10 mg/kg) and levorphanol (20 mg/kg) were less marked. Dextrorphan (20 mg/kg), diazepam (10 mg/kg) and pentobarbital (20 mg/kg) administration did not significantly increase opioid-like activity in CSF. It is concluded that the antinociceptive action of some opioid analgesics in rabbits may be mediated in part by the release of endogenous antinociceptive substances.

Animals↗

Effects of branched-chain amino acids on beta-endorphin in the pituitary of the rat.

Despite evidence that the branched-chain amino acids (BCAAs) influence brain metabolism and neurotransmitter synthesis, there is little information on the neuroendocrine effects of the BCAAs. We now report that administration of a mixture of the BCAAs 3 times daily for 12 days to Sprague-Dawley rats decreased the concentration of beta-endorphin immunoreactivity (BEI) in the neurointermediate lobe of the pituitary. In BCAA-treated rats, BEI was 21 +/- 4 compared to control levels of 57 +/- 12 (ng/microgram of protein). The BCAAs had no effect on the level of BEI in the adenohypophysis. These findings suggest that changes in availability of leucine, isoleucine, and valine mediate specific neuroendocrine responses to metabolic perturbations in the rat.

Amino Acids, Branched-Chain↗

Cholinergic agents: antinociception without morphine type dependence in rats.

We have confirmed the work of others showing that loss in body weight is a predictable and consistent sign of opiate withdrawal in rats. Rats that were treated chronically with either oxotremorine or physostigmine displayed no weight loss or other signs of opiate-like withdrawal when the drugs were withdrawn. Furthermore, there was no difference in weight loss between morphine dependent rats substituted with saline and those substituted with either cholinergic drug. However, we did observe an increased mortality among rats substituted with a cholinergic agent compared with saline. Rats infused with a mixture of morphine plus oxotremorine or morphine plus physostigmine showed less weight loss, but not fewer behavioral signs, after the end of the infusion than rats treated only with morphine. It is concluded that the cholinergic agents did not cause a morphine-like physical dependence themselves, but appeared to antagonize to some extent the development or manifestation of opiate dependence.

Analgesics↗

Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.

Several C-10 substituted cannabidiol (CBD) derivatives and novel oxepin derivatives of delta 9-tetrahydrocannabinol (delta 9-THC) were synthesized and evaluated for biological activity in mice and dogs. Treatment of 10-bromocannabidiol diacetate (3) with various amines in Me2SO gave the corresponding 10-aminocannabidiol derivatives 4-6. Similarly, treatment of 3 with NaN3 gave the azido compound 7, which with LiA1H4 afforded the 10-aminocannabidiol 9. However, reduction of 7 with CrCl2 formed the amide 8, which on further reduction with LiA1H4 gave the N-ethyl analogue 10. Coupling of 9 with 11 in the presence of dicyclohexylcarbodiimide formed 12, which was then deprotected with HCl to give the analogue 13. The oxepin analogue 14a was synthesized from 3 by treatment with Na2CO3 in CH3OH/H2O at room temperature. The dimethylheptyl analogue 14b was similarly prepared. Incorporation of N-ethyl (10), N-methyl-N-propargyl (6), and morpholino (4) groups in CBD at position 10 resulted in analogues that were more potent than CBD in producing hypoactivity in mice. These analogues had relatively little effect on rectal temperature. Selected substitutions at C-10 also resulted in analogues that were partially effective in blocking delta 9-THC antinociceptive activity. This blockade was observed particularly in compound 10, which also showed unusually toxic properties. Incorporation of a seven-membered oxepin in the delta 9-THC structure eliminated cannabinoid activity although substitution of the pentyl side chain with a 1,2-dimethylheptyl in the oxepin 14b resulted in CNS depression in mice.

Analgesics↗

Failure of branched-chain amino acids to affect synaptosomal uptake of norepinephrine and dopamine.

Despite evidence for neuroendocrine actions of the branched-chain amino acids (BCAAs) and implications that these amino acids alter the turnover of central catecholamines, the mechanism of these actions of the BCAAs is uncertain. In this study, we tested the effects of the BCAAs on uptake of catecholamines by axon terminals (synaptosomes) isolated from whole mouse brain minus the cerebellum. Neither high physiological (1-2 mM) nor pharmacological levels (10 mM) of an equimolar mixture of the BCAAs altered the uptake of 3H-dopamine and 3H-norepinephrine by synaptosomes. These findings suggest that the BCAAs do not influence the reuptake mechanism for termination of catecholamine-mediated neurotransmission.

Amino Acids, Branched-Chain↗

Stereoselective stimulus effects of 3-methylflunitrazepam and pentobarbital.

Rats trained to discriminate 3.0 mg/kg of diazepam from saline in a two-lever operant choice task were challenged with the racemic mixture and optical isomers of 3- methylflunitrazepam or pentobarbital. Generalization of the diazepam stimulus was found to occur to (+/-)- and S(+)-3- methylflunitrazepam , with the S(+)-isomer being twice as active as the racemate. Diazepam stimulus generalization also occurred to (+/-)-, S(-)-, and R(+)-pentobarbital, with the S(-)-isomer being approximately twice as active as (+/-)- or R(+)-pentobarbital. In addition, the administration of the imidazobenzodiazepine Ro 15-1788, a selective benzodiazepine receptor antagonist, prior to benzodiazepine or barbiturate administration competitively antagonized the discriminative stimulus properties of the benzodiazepines but was completely ineffective in attenuating the discriminative stimulus effect of the barbiturates. The results of this study suggest that benzodiazepines exert their stimulus effects by a stereoselective interaction at a benzodiazepine receptor and that stereochemical factors are important in evaluating the stimulus properties of benzodiazepines or barbiturates.

Animals↗

The discriminative stimulus properties of the R2 isomer of viminol.

Viminol is a pyrrylethanolamine derivative which exists naturally as a racemic mixture containing six different stereoisomers. Viminol has been reported to exert both potent analgesic activity and minimal dependence liability. The analgesic component of racemic viminol has been attributed to the R2 isomer, while the antagonistic S2 isomer appears to be responsible for minimizing the dependence liability of the racemate. We tested the R2 isomer of viminol in rats trained to discriminate 3 mg/kg morphine sulfate from saline on a VI-15 sec schedule for sweetened milk reinforcement. The R2 isomer resulted in dose dependent morphine-like responding, with complete generalization to the 2.5 mg/kg dose of R2 viminol. The morphine-like discriminative stimulus properties of R2 viminol were reversed by naloxone in a dose-dependent fashion, with total blockade by 0.1 mg/kg naloxone. R2 viminol, like morphine, also had a biphasic effect on response rate with low doses increasing and high doses suppressing response rates. R2 viminol had a overall shorter time course than that reported for morphine, and its different physiological and behavioral effects may not occur simultaneously. These data suggest that R2 viminol exerts a subjective effect similar to that of morphine and supports the hypothesis that R2 viminol has opiate activity despite its lack of structural relationship to the opiate series.

Animals↗

Pharmacological potency of R- and S-3'-hydroxy-delta 9-tetrahydrocannabinol: additional structural requirement for cannabinoid activity.

The pharmacological potency of R- and S-3'-hydroxy-delta 9-tetrahydrocannabinol (THC) was compared to that of delta 9-THC as well as R/S-3'-OH-delta 9-THC. The S-isomer was found to be considerably more potent than the R-isomer in producing hypoactivity in mice, static-ataxia in dogs, and in generalization testing in rats trained to discriminate delta 9-THC from vehicle. S-3'-OH-delta 9-THC was more active than delta 9-THC in these tests which means that delta 9-THC may be either activated or inactivated in vivo depending upon which metabolite is formed. The difference in potency of these isomers suggests that the conformation of the side chain is critical for behavioral activity. The R and S isomers were found to be equally active in producing hypothermia in mice which is in contrast to the behavioral effects.

Animals↗

Characterization of the interaction of pentazocine and tripelennamine: drug discrimination and mu-receptor binding assay.

Abuse of the combination of pentazocine (P) and tripelennamine (T) reputedly produces an opiate-like euphoria not obtainable from either drug alone. To determine if this effect is related to interactions at the behavioral or receptor levels we tested this combination in rats trained to discriminate morphine from saline and in mu-receptor binding assays. Displacement of 3H-DHM was compared in morphine-naive, dependent and withdrawn states to determine the importance of prior morphine exposure. The morphine training cue (3 mg/kg) generalized to P but not to T. Combinations of T (0.3 and 1.0 mg/kg) with "no effect" doses of P (1 and 3 mg/kg) resulted in greater than additive increases in morphine-like responding. 3H-DHM was displaced by P but not T in naive, dependent and withdrawn states. Specific dose combinations of T (1 nM) with P (1 nM, 10 nM, 100 nM) resulted in enhanced displacement of 3H-DHM and was not related to prior morphine exposure. We conclude that the addition of T to P increases the mu-like subjective effects of P and this effect may be due to enhanced affinity of P for the mu-receptor.

Animals↗

Synthesis and pharmacological activity of some 9-substituted delta 8-tetrahydrocannabinol analogues.

Several 9-substituted delta 8-tetrahydrocannabinol (delta 8-THC) analogues were synthesized and evaluated for biological activity in mice. Compounds with phenyl (2b) and butyl (2c) substituents were prepared by the addition of phenyllithium and n-butyllithium, respectively, to (-)-9-nor-9-oxohexahydrocannabinol (1), followed by dehydration, whereas, isopropyl (2d), PhCH2 (2e), and Ph(CH2)2 (2f) derivatives were synthesized via the Grignard reaction with subsequent dehydration. Compounds with C2H5CH(OH) (2g) and CH3CH(OH) (2h) substituents at C-9 were prepared from (-)-9-nor-9-formyl-delta 8-tetrahydrocannabinol acetate (3) by the reaction of ethyl and methyl Grignard reagents, respectively. Biological activity indicated that a methyl group at the C-9 position is, thus far, optimum for producing hypoactivity and hypothermia in mice. In addition, hydroxyethyl substitution at position 9 reduced and antinociceptive activity of delta 8-THC, in contrast to the increased activity reported for hydroxymethyl substitution.

Analgesia↗

Pentazocine-tripelennamine ("T's and Blues") substitution studies in morphine-dependent rodents.

Tripelennamine, pentazocine and various pentazocine-tripelennamine combinations were tested for their ability to substitute for morphine in morphine-dependent rodents. Rats and mice were rendered physically dependent on morphine by the Drug-Admixed Food Method. Pentazocine produced a dose-related partial suppression of morphine withdrawal signs in mice, as well as in both mildly and severely dependent rats. Tripelennamine did not suppress morphine withdrawal signs, but rather aggravated them. Furthermore, tripelennamine did not potentiate the ability of pentazocine to suppress morphine withdrawal signs. It is concluded that the primary reason for the reported "street" abuse of the tripelennamine-pentazocine combinations is not related to any remarkable ability of the combination to effectively suppress the discomfort of heroin withdrawal.

Animals↗

Potentiation of narcotic-induced antinociception by tripelennamine in morphine-tolerant and drug-naive mice.

The ability of tripelennamine and chlorpheniramine to potentiate morphine- and pentazocine-induced antinociception in drug-naive and morphine-tolerant mice was tested utilizing the hot-plate method. Both tripelennamine and chlorpheniramine alone produced dose-dependent increases in hot plate latency which were naloxone reversible. Cross-tolerance developed between tripelennamine and morphine, whereas no cross-tolerance developed between chlorpheniramine and morphine. Neither tripelennamine nor chlorpheniramine significantly potentiated morphine-induced antinociception in drug-naive mice. The effects of tripelennamine and morphine were additive. Tripelennamine but not chlorpheniramine, however, significantly potentiated antinociception produced by low but not high doses of pentazocine in drug-naive mice. Furthermore, in morphine-tolerant mice, tripelennamine, but not chlorpheniramine, potentiated both morphine- and pentazocine-induced antinociception. It is concluded that the abuse of various narcotic-tripelennamine combinations can be attributed, at least in part, to a specific property of tripelennamine to potentiate narcotic effects in the drug-naive and morphine-tolerant state.

Analgesia↗